Genelabs is a biopharmaceutical company focused on the discovery and development of novel compounds for infectious diseases. In addition to a late-stage drug candidate for Hepatitis E partnered with GlaxoSmithKline, the company is advancing multiple partnered and proprietary compounds designed to selectively inhibit replication of the hepatitis C virus, targeting the HCV viral proteins - NS5B polymerase, NS4B, and NS5A. In January 2009 Genelabs was bought by GlaxoSmithKline.
Company Details
- Phone
- 650-369-9500
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- genelabs.com
- Keywords
- Sri Biotech Lanka (PVT) Ltd.
Genelabs Technologies Questions
Genelabs Technologies's helpline number is 650-369-9500
Genelabs Technologies's website is genelabs.com
Genelabs Technologies's LinkedIn profile is https://www.linkedin.com/company/genelabs-technologies
Genelabs Technologies's industry is
Biotechnology Research
Genelabs Technologies's top competitors are
Genepace Laboratories,
Genetech,
Hologic (Formerly Gen-Probe),
Carogen Corporation,
Sri Biotech Lanka (Pvt) Ltd,
Hayleys Agro Biotech Pvt Ltd, Srilanka,
Genelabs,
Cor Therapeutics,
Biomedx,
Genelabs Medical (Pvt) Ltd.
Genelabs Technologies's categories are Biotechnology Research
